Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Cerilliant
Colorcon
QuintilesIMS
Chinese Patent Office
Merck
Express Scripts
US Army
Harvard Business School

Generated: August 20, 2018

DrugPatentWatch Database Preview

Eli Lilly Co Company Profile

« Back to Dashboard

Summary for Eli Lilly Co
International Patents:279
US Patents:4
Tradenames:2
Ingredients:2
NDAs:2
Drug Master File Entries: 1

Drugs and US Patents for Eli Lilly Co

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Eli Lilly Co ZYPREXA RELPREVV olanzapine pamoate SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 022173-002 Dec 11, 2009 RX Yes No 6,169,084 ➤ Sign Up Y Y ➤ Sign Up
Eli Lilly Co ADCIRCA tadalafil TABLET;ORAL 022332-001 May 22, 2009 AB RX Yes Yes 5,859,006*PED ➤ Sign Up ➤ Sign Up
Eli Lilly Co ADCIRCA tadalafil TABLET;ORAL 022332-001 May 22, 2009 AB RX Yes Yes 6,821,975*PED ➤ Sign Up Y ➤ Sign Up
Eli Lilly Co ADCIRCA tadalafil TABLET;ORAL 022332-001 May 22, 2009 AB RX Yes Yes 7,182,958*PED ➤ Sign Up Y ➤ Sign Up
Eli Lilly Co ZYPREXA RELPREVV olanzapine pamoate SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 022173-003 Dec 11, 2009 RX Yes Yes 6,169,084 ➤ Sign Up Y Y ➤ Sign Up
Eli Lilly Co ZYPREXA RELPREVV olanzapine pamoate SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 022173-001 Dec 11, 2009 RX Yes No 6,169,084 ➤ Sign Up Y Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for Eli Lilly Co

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Eli Lilly Co ZYPREXA RELPREVV olanzapine pamoate SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 022173-001 Dec 11, 2009 5,229,382*PED ➤ Sign Up
Eli Lilly Co ZYPREXA RELPREVV olanzapine pamoate SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 022173-003 Dec 11, 2009 5,229,382*PED ➤ Sign Up
Eli Lilly Co ZYPREXA RELPREVV olanzapine pamoate SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 022173-002 Dec 11, 2009 5,229,382*PED ➤ Sign Up
Eli Lilly Co ADCIRCA tadalafil TABLET;ORAL 022332-001 May 22, 2009 5,859,006*PED ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for ELI LILLY CO drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Tablets 20 mg ➤ Subscribe 2009-10-15

Non-Orange Book US Patents for Eli Lilly Co

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,841,167 .beta.-carboline pharmaceutical compositions ➤ Sign Up
6,784,179 Tetracyclic derivatives, process of preparation and use ➤ Sign Up
6,617,321 2-methyl-thieno-benzodiazepine formulation ➤ Sign Up
5,981,527 Cyclic GMP-specific phosphodiesterase inhibitors ➤ Sign Up
7,303,764 2-methyl-thieno-benzodiazepine formulation ➤ Sign Up
6,143,746 Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use ➤ Sign Up
6,127,542 Tetracyclic derivatives, process of preparation and use ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for Eli Lilly Co Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2003 00008 Denmark ➤ Sign Up
0813 Netherlands ➤ Sign Up PRODUCT NAME: AMBRISENTAN TOEGEPAST IN COMBINATIEBEHANDELING MET TADALAFIL; REGISTRATION NO/DATE: EU/1/08/451 (C(2008) 1637) 20151125
C/GB03/007 United Kingdom ➤ Sign Up PRODUCT NAME: TADALAFIL AND PHARMACEUTICALLY ACCEPTABLE SALTS, ESTERS AND SOLVATES THEREOF.; REGISTERED: UK EU/1/02/237/001-004 20021114
C0017 France ➤ Sign Up PRODUCT NAME: TADALAFIL; REGISTRATION NO/DATE: EU/1/02/237/001-004 20021112
2016 00024 Denmark ➤ Sign Up PRODUCT NAME: AMBRISENTAN USED IN COMBINATION TREATMENT WITH TADALAFIL; REG. NO/DATE: EU/1/08/451 (001-004) 20151125
0740668/01 Switzerland ➤ Sign Up PRODUCT NAME: TADALAFILUM; REGISTRATION NUMBER/DATE: SWISSMEDIC 56018 04.05.2004
2016000039 Germany ➤ Sign Up PRODUCT NAME: AMBRISENTAN IN VERWENDUNG IN DER KOMBINATIONSTHERAPIE MIT TADALAFIL; REGISTRATION NO/DATE: EU/1/08/451 20151120
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Chubb
Boehringer Ingelheim
Dow
Citi
Baxter
Farmers Insurance
Queensland Health
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.